Expression profiling of metastatic renal cell carcinoma using gene set enrichment analysis

International Journal of Urology

Volumn 21, Issue 1, 2014, Pages 46-51

  Maruschke, Matthias ^a   Hakenberg, Oliver W ^a   Koczan, Dirk ^a   Zimmermann, Wolfgang ^b   Stief, Christian G ^c   Buchner, Alexander ^c  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Biomarker; Gene expression; Gene set enrichment analysis; Metastasis; Renal cell carcinoma

Indexed keywords

AURORA A KINASE; DEOXYRIBONUCLEASE I;

ADRENAL METASTASIS; ADULT; AGED; APOPTOSIS; ARTICLE; CELL ADHESION; CELL CYCLE REGULATION; CELL METABOLISM; CELL MOTILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSKELETON; DISEASE SEVERITY; DISTANT METASTASIS; DNA MICROARRAY; DOWN REGULATION; ENZYME STRUCTURE; FEMALE; GENE CONTROL; GENE EXPRESSION; GENETIC ALGORITHM; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MIDDLE AGED; PRIMARY TUMOR; PRIORITY JOURNAL; UPREGULATION; YOUNG ADULT;

BIOMARKER; GENE EXPRESSION; GENE SET ENRICHMENT ANALYSIS; METASTASIS; RENAL CELL CARCINOMA;

AGED; ALGORITHMS; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED;

EID: 84891556431     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12183     Document Type: Article

References (25)

1. Levi F, Ferlay J, Galeone C etal. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int. 2008; 101: 949-958.
2. Ljungberg B, Hanbury DC, Kuczyk MA etal. Renal cell carcinoma guideline. Eur. Urol. 2007; 51: 1502-1510.
3. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J. Urol. 2005; 23: 202-212.
4. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. U.S.A. 2001; 98: 31-36.
5. Subramanian A, Tamayo P, Mootha VK etal. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 2005; 102: 15545-15550.
6. Maruschke M, Reuter D, Koczan D, Hakenberg OW, Thiesen HJ. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management. BJU Int. 2011; 108: E29-35.
7. Liu BH, Goh CH, Ooi LL, Hui KM. Identification of unique and common low abundance tumour-specific transcripts by suppression subtractive hybridization and oligonucleotide probe array analysis. Oncogene 2008; 27: 4128-4136.
8. Bracarda S, Sisani M, Del Buono S, Ishiwa O, Montagnani F. Biologic tools to personalize treatment in genitourinary cancers. Crit. Rev. Oncol. Hematol. 2012; 84 (Suppl 1): e42-48.
9. Maruschke M, Koczan D, Reuter D etal. Putative biomarker genes for grading clear cell renal cell carcinoma. Urol. Int. 2011; 87: 205-217.
10. Nam D, Kim SY. Gene-set approach for expression pattern analysis. Brief. Bioinform. 2008; 9: 189-197.
11. Gakiopoulou H, Korkolopoulou P, Levidou G etal. Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications. Br. J. Cancer 2007; 97: 1124-1134.
12. Barton VN, Foreman NK, Donson AM, Birks DK, Handler MH, Vibhakar R. Aurora kinase A as a rational target for therapy in glioblastoma. J. Neurosurg. Pediatr. 2010; 6: 98-105.
13. Tanaka H, Nakashiro KI, Iwamoto K etal. Targeting Aurora kinase A suppresses the growth of human oral squamous cell carcinoma cells in vitro and in vivo. Oral Oncol. 2013; doi: 10.1016/j.oraloncology.2013.02.002.
14. Gorgun G, Calabrese E, Hideshima T etal. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 2010; 115: 5202-5213.
15. Siggelkow W, Boehm D, Gebhard S etal. Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients. BMC Cancer 2012; 12: 562-573.
16. Panda H, Jaiswal AS, Corsino PE, Armas ML, Law BK, Narayan S. Amino acid Asp181 of 5'-flap endonuclease 1 is a useful target for chemotherapeutic development. Biochemistry 2009; 48: 9952-9958.
17. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J. Urol. 2005; 173: 1853-1862.
18. Kosari F, Parker AS, Kube DM etal. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin. Cancer Res. 2005; 11: 5128-5139.
19. Jones J, Otu H, Spentzos D etal. Gene signatures of progression and metastasis in renal cell cancer. Clin. Cancer Res. 2005; 11: 5730-5739.
20. Ronkainen H, Hirvikoski P, Kauppila S, Vaarala MH. Anillin expression is a marker of favourable prognosis in patients with renal cell carcinoma. Oncol. Rep. 2011; 25: 129-133.
21. Searchfield L, Price SA, Betton G, Jasani B, Riccardi D, Griffiths DF. Glutathione S-transferases as molecular markers of tumour progression and prognosis in renal cell carcinoma. Histopathology 2011; 58: 180-190.
22. Macher-Goeppinger S, Bermejo JL, Wagener N etal. Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas. Cancer Lett. 2011; 301: 203-211.
23. Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Eur. Urol. 2007; 52: 1601-1609.
24. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann. Intern. Med. 1999; 130: 515-524.
25. Bleeker SE, Moll HA, Steyerberg EW etal. External validation is necessary in prediction research: a clinical example. J. Clin. Epidemiol. 2003; 56: 826-832.